High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

MLA

Kinlay, Scott, et al. “High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients with Acute Coronary Syndromes in the MIRACL Study.” Circulation, vol. 108, no. 13, Sept. 2003, pp. 1560–66. EBSCOhost, https://doi.org/10.1161/01.CIR.0000091404.09558.AF.

APA

Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M., Libby, P., & Ganz, P. (2003). High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation, 108(13), 1560–1566. https://doi.org/10.1161/01.CIR.0000091404.09558.AF

Chicago

Kinlay, Scott, Gregory G Schwartz, Anders G Olsson, Nader Rifai, Sally J Leslie, William J Sasiela, Michael Szarek, Peter Libby, and Peter Ganz. 2003. “High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients with Acute Coronary Syndromes in the MIRACL Study.” Circulation 108 (13): 1560–66. doi:10.1161/01.CIR.0000091404.09558.AF.